Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia (ITP)
The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia|
|Study Start Date:||November 2011|
|Study Completion Date:||August 2012|
|Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
Rapamycin, an immunosuppressive drug, is widely used to prevent allograft rejection and autoimmune diseases. Many studies have shown that the drug contributes to the expansion of regulatory T cells and preserves the highly suppressive function of autoreactive T cells. Patients with RITP often display a decreased proportion of regulatory T cells by flow cytometer, therefore, the investigators will examine the efficacy of rapamycin in RITP patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01672151
|Jiangsu Institute of Hematology|
|Suzhou, Jiangsu, China, 215006|
|Study Director:||zhaoyue wang, doctor|